M&A Deal Summary

Biotage AB Acquires ATDBio

On October 20, 2021, Biotage AB acquired life science company ATDBio for 45M GBP

Acquisition Highlights
  • This is Biotage AB’s 3rd transaction in the Life Science sector.
  • This is Biotage AB’s largest (disclosed) transaction.
  • This is Biotage AB’s 1st transaction in the United Kingdom.

M&A Deal Summary

Date 2021-10-20
Target ATDBio
Sector Life Science
Buyer(s) Biotage AB
Deal Type Add-on Acquisition
Deal Value 45M GBP

Target

ATDBio

Southampton, United Kingdom
website
ATDBio is a complex oligonucleotide synthesis with expertise in highly complex DNA and RNA production. ATDBio works on molecular diagnostics, nucleic acid-based therapeutics, and vaccines plus new generation DNA and RNA sequencing technologies. ATDBio was founded in 2005 and is based in Southampton, United Kingdom.

Search 193,974 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Biotage AB

Uppsala, Sweden

website


Category Company
Sector Life Science
Employees284
Revenue 490M SEK (2014)
DESCRIPTION

Biotage AB is a Swedish company offering solutions within two fields: pharmaceutical chemistry, conducted in the Discovery chemistry business, and genetic analysis, which makes up the Biosystems business unit.


DEAL STATS #
Overall 6 of 6
Sector (Life Science) 3 of 3
Type (Add-on Acquisition) 5 of 5
Country (United Kingdom) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-12-04 PhyNexus

San Jose, California, United States

PhyNexus, Inc. offers protein and plasmid sample preparation columns and robotics. PhyNexus products miniaturize and automate purification while retaining the native state of the protein and/or provide transient transfection quality plasmids. PhyNexus, Inc. was founded in 2002 and is based in San Jose, California.

Buy -